Comparison of Effects of Propofol Combined with Different Doses of Esketamine for ECT in the Treatment of Depression: A Randomized Controlled Trial Protocol

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2024 May 22

PMID 38774255

Authors

Xuemeng Chen

Rui Zhou

Lan Lan

Ling Zhu

Cheng Chen

Xianjie Zhang

Jia Han

Leqiang Xia

Affiliations

Soon will be listed here.

Abstract

Objective: Major depressive disorder (MDD) is a common mood disorder. Electroconvulsive therapy (ECT) has a significant effect on treatment-resistant MDD. Esketamine may have potential advantages in improving the efficacy of ECT, and the strong affinity of this compound for NMDAR renders it a viable therapeutic option for the management of depression. This study aims to compare the effects of different doses of esketamine combined with propofol anesthesia versus propofol anesthesia alone in ECT, aiming to provide further insights for optimizing ECT and enhancing comprehensive treatment outcomes for depression.

Study Design And Methods: This study was a prospective, randomized, controlled, double-blind trial involving subjects and evaluators. One hundred eleven patients scheduled for ECT were randomly assigned to three groups. In Group P, propofol at 1mg/kg was administered intravenously. In Group P+E, propofol at a dosage of 0.5mg/kg and esketamine at a dosage of 0.5mg/kg was administered intravenously. Patients in Group P+SE received propofol at a dosage of 0.75mg/kg and esketamine at a dosage of 0.25mg/kg. The same anesthesia protocol was used for the same patient until the end of the last treatment. The primary outcome measures were the Hamilton depression scale (HAMD) and the Patient Health Questionnaire-9 (PHQ-9), the Columbia-Suicide Severity Rating Scale (C-SSRS), and the Digit symbol substitution test (DSST). Secondary outcomes included length of hospital stay, readmission rate, hemodynamic status, recovery, and adverse events.

Discussion: This study aimed to compare the effects of propofol combined with different doses of esketamine for ECT. The results may provide a better choice for ECT anesthesia.

References

Zimmerman M, Martinez J, Young D, Chelminski I, Dalrymple K . Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013; 150(2):384-8. DOI: 10.1016/j.jad.2013.04.028. View

Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266-77. PMC: 3893686. DOI: 10.1176/appi.ajp.2011.10111704. View

Bahji A, Vazquez G, Zarate Jr C . Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2020; 278:542-555. PMC: 7704936. DOI: 10.1016/j.jad.2020.09.071. View

Ionescu D, Fu D, Qiu X, Lane R, Lim P, Kasper S . Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol. 2020; 24(1):22-31. PMC: 7816667. DOI: 10.1093/ijnp/pyaa068. View

Brown S, Nowlin R, Sartorelli R, Smith J, Johnson K . Patient Experience of Electroconvulsive Therapy: A Retrospective Review of Clinical Outcomes and Satisfaction. J ECT. 2018; 34(4):240-246. DOI: 10.1097/YCT.0000000000000492. View

Xu L, Wang C, Deng C, Dai S, Zhou Q, Peng Y . Efficacy and Safety of Esketamine for Supplemental Analgesia During Elective Cesarean Delivery: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(4):e239321. PMC: 10122167. DOI: 10.1001/jamanetworkopen.2023.9321. View

Hsieh M . Electroconvulsive therapy for treatment-resistant depression. Prog Brain Res. 2023; 281:69-90. DOI: 10.1016/bs.pbr.2023.01.004. View

Castaneda-Ramirez S, Becker T, Bruges-Boude A, Kellner C, Rice T . Systematic review: Electroconvulsive therapy for treatment-resistant mood disorders in children and adolescents. Eur Child Adolesc Psychiatry. 2022; 32(9):1529-1560. DOI: 10.1007/s00787-022-01942-7. View

Rhee T, Sint K, Olfson M, Gerhard T, Busch S, Wilkinson S . Association of ECT With Risks of All-Cause Mortality and Suicide in Older Medicare Patients. Am J Psychiatry. 2021; 178(12):1089-1097. PMC: 8639649. DOI: 10.1176/appi.ajp.2021.21040351. View

10.

Voineskos D, Daskalakis Z, Blumberger D . Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr Dis Treat. 2020; 16:221-234. PMC: 6982454. DOI: 10.2147/NDT.S198774. View

11.

Lima T, Visacri M, Aguiar P . Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. Eur J Clin Pharmacol. 2021; 78(3):311-338. DOI: 10.1007/s00228-021-03216-8. View

12.

Jauhar S, Morrison P . Esketamine for treatment resistant depression. BMJ. 2019; 366:l5572. DOI: 10.1136/bmj.l5572. View

13.

Singh B, Kung S, Pazdernik V, Schak K, Geske J, Schulte P . Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023; 84(2). DOI: 10.4088/JCP.22m14548. View

14.

Levis B, Benedetti A, Thombs B . Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019; 365:l1476. PMC: 6454318. DOI: 10.1136/bmj.l1476. View

15.

Malhi G, Mann J . Depression. Lancet. 2018; 392(10161):2299-2312. DOI: 10.1016/S0140-6736(18)31948-2. View

16.

Espinoza R, Kellner C . Electroconvulsive Therapy. N Engl J Med. 2022; 386(7):667-672. DOI: 10.1056/NEJMra2034954. View

17.

Zhou Y, Lan X, Wang C, Zhang F, Liu H, Fu L . Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2023; 63(5):507-518. DOI: 10.1016/j.jaac.2023.05.031. View

18.

Lin H, Liu S, Hsieh M, Chien Y, Chen I, Liao S . Impacts of Electroconvulsive Therapy on 1-Year Outcomes in Patients With Schizophrenia: A Controlled, Population-Based Mirror-Image Study. Schizophr Bull. 2017; 44(4):798-806. PMC: 6007329. DOI: 10.1093/schbul/sbx136. View

19.

Gamble J, Bi H, Bowen R, Weisgerber G, Sanjanwala R, Prasad R . Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study. Can J Anaesth. 2018; 65(6):636-646. DOI: 10.1007/s12630-018-1088-0. View

20.

Tor P, Tan X, Martin D, Loo C . Comparative outcomes in electroconvulsive therapy (ECT): A naturalistic comparison between outcomes in psychosis, mania, depression, psychotic depression and catatonia. Eur Neuropsychopharmacol. 2021; 51:43-54. DOI: 10.1016/j.euroneuro.2021.04.023. View